Cargando…

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study

BACKGROUND: There is no consensus on the optimal secondary antifungal prophylaxis (SAP) regimen in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). The purpose of this study was to evaluate the efficacy and safety of posaconazole oral suspension as secondary prophyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Peipei, Pei, Renzhi, Hu, Youqian, Chen, Dong, Li, Shuangyue, Cao, Junjie, Li, Fenglin, Wu, Mengjie, Fang, Ying, Lu, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107735/ https://www.ncbi.nlm.nih.gov/pubmed/35570276 http://dx.doi.org/10.1186/s12879-022-07442-y

Ejemplares similares

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

2736. Real-world Effectiveness of Posaconazole Prophylaxis in Preventing Invasive Fungal Infections in Recipients of Allogeneic Stem Cell Transplantation
por: Álvarez-Ortega, Carolina, et al.
Publicado: (2023)

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation
por: Döring, Michaela, et al.
Publicado: (2012)

Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
por: Takpradit, Chayamon, et al.
Publicado: (2021)

Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients
por: Ju, Chunrong, et al.
Publicado: (2022)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study
por: Özkocaman, Vildan, et al.
Publicado: (2018)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

412. Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis With Continuous Micafungin Compared to Posaconazole With Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A 6-Year Cohort Analysis
por: Heimann, Sebastian M, et al.
Publicado: (2018)

Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to Polypharmacotherapy
por: Sienkiewicz-Oleszkiewicz, Beata, et al.
Publicado: (2019)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021)

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study
por: Kung, Hsiang-Chi, et al.
Publicado: (2014)

Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation
por: Yuan, Jiaojiao, et al.
Publicado: (2017)

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
por: Lindsay, Julian, et al.
Publicado: (2021)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
por: Perreault, Sarah, et al.
Publicado: (2023)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Cost-Effectiveness of Targeted Prophylaxis among Allogenic Stem Cell Transplant Recipients
por: Shbaklo, Nour, et al.
Publicado: (2023)

Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report
por: Mody, Mayur D., et al.
Publicado: (2017)

Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model
por: Dvořáčková, Eliška, et al.
Publicado: (2023)

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
por: Bow, Eric J, et al.
Publicado: (2015)

Real-World Experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Single-Center Study
por: Chan, Shuk-Ying, et al.
Publicado: (2017)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis
por: de Macedo-Silva, Sara Teixeira, et al.
Publicado: (2013)

Pulmonary Phaeohyphomycosis Caused by Phaeoacremonium in a Kidney Transplant Recipient: Successful Treatment with Posaconazole
por: Monaganti, Saivaralaxmi, et al.
Publicado: (2014)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents
por: Shah, Nishi, et al.
Publicado: (2014)

Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies
por: Suh, Hyeon Jeong, et al.
Publicado: (2017)

Sample Preparation of Posaconazole Oral Suspensions for Identification of the Crystal Form of the Active Pharmaceutical Ingredient
por: Lykouras, Michail, et al.
Publicado: (2020)

Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans
por: Chen, Ying-Lien, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jmq4o7k2mcg9smai92l0rvo152